Galina Marder, MD

Director, Inflammatory Muscle Disease and Vasculitis Center, Northwell Health

Director, Arthritis Clinic, LIJ Medical Center, Northwell Health

Assistant Professor of Medicine, Hofstra Northwell School of Medicine

Phone: (516) 708-2550

About the Investigator

Dr. Marder is an attending physician with the Division of Rheumatology and she is involved in many clinical trials relating specifically to myositis as well as other autoimmune diseases.

Research Focus

Inflammatory muscle disease
Systemic lupus erythematosus


Hospital for joint Disease NYU
Degree: Fellowship

North Shore Univeristy Hospital, Forest Hills
Degree: Resident

Novosibirsk State Medical School
Degree: MD

Honors and Awards

2015 GlaxoSmithKline IIS Award

  1. Rothwell S et al and Myositis Genetics Consortium. “Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for many clinical subgroups.” Ann Rheum Dis. Sep 11, 2015
  2. Yzadany J, Erkan D, Sanchez-Guerrero J, Hahn B, Levine A, Marder G, McCune J, Joseph W Post-Marketing experience with Belimumab in US lupus centers: data from The Lupus Clincial Trials Consortium, Inc. (LCTC) National Patient Registry. Arthritis & Rheumatism, Volume 65, October 2013 Abstract Supplement
  3. Chester V. Oddis, Ann M. Reed, Rohit Aggarwal, Lisa G. Rider, Dana P. Ascherman, Marc C. Levesque, Richard J. Barohn, Brian M. Feldman, Michael O. Harris-Love, Diane C. Koontz, Noreen Fertig, Stephanie S. Kelley, Sherrie L. Pryber, Fredrick W. Miller, Howard E. Rockette and the RIM Study Group. “Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial.” Arthritis Rheum. February 2013, v65, issue 2, p314-324.
  4. Aggarwal R, reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love M, Levesque M, Oddis C, the RIM Study Group. “Clinical and serologic predictors of response in Rituximab-treated refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) – the RIM Study.” Arthritis Rheum 2012; 64 Suppl 10 : 1598
  5. Katzap E, Barilla-Labarca ML, Marder G. “Antisynthetase syndrome.” Curr Rheumatol Rep. 2011 Jun; 13(3): 175-81.
  6. C Tseng, J Buyon, M Kim, HM Belmont, M MacKay, B Diamond, G Marder, P Rosenthal, K Haines, VIlie, S Abramson. “Moderate Dose Steroids Prevent Severe Flares in a Prospective Mulitcenter Study of Serlogoically Active Clinically Stable Systemic Lupus Erythematosus (SLE) patients.” Arthritis & Rheumatism, 2006, vol54, No 11.pp3623-3632
  7. Belostosky O, Diamond A, Marder G. “TNF-Alpha inhibitors in treatment of refractory sarcoidosis with severe CNS Involvement: 65.” Journal of Allergy & Clinical Immunology. 115(2) Supplement 1:S17, February 2005.
  8. Marder G and Greenwald RA. “Potential applications of matrix metalloproteinase inhibitors (MMPIs) in geriatric practice.” The Israel Medical Association Journal 2003; 5(5) 361-364.
  9. Anita K, Marder G, Mattana J. “Severe upper airway obstruction from cricoartenoiditis as the sole presenting manifestation of a Systemic Lupus Erythematosus Flare.” Chest. 12193):990-993, March 2002.
  10. Clancy R, Marder G, Martin V, Belmont HM, Abramson S, Buyon J. “Circulating activated endothelial cells in Systemic Lupus Erythematosus: further evidence for diffuse vasculopathy.” Arthritis & Rheumatism. 44(5):1203-1208, May 2001.
  11. Marder, G; Buyon, J; Belmont, M; Abramson, SB; Clancy, R. “Circulating Activated Endothelial Cells in SLE: Further Evidence for Diffuse Vasculopathy.” Arthritis & Rheumatism. 42(9) Supplement, S306, September 1999.

View more at PubMed